PHATHOM PHARMACEUTICALS INC's ticker is PHAT and the CUSIP is 71722W107. A total of 104 filers reported holding PHATHOM PHARMACEUTICALS INC in Q2 2023. The put-call ratio across all filers is 0.20 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $2 | 0.0% | 167 | 0.0% | 0.00% | – |
| Q1 2024 | $2 | 0.0% | 167 | 0.0% | 0.00% | – |
| Q4 2023 | $2 | 0.0% | 167 | 0.0% | 0.00% | – |
| Q3 2023 | $2 | 0.0% | 167 | 0.0% | 0.00% | – |
| Q2 2023 | $2 | +100.0% | 167 | 0.0% | 0.00% | – |
| Q1 2023 | $1 | -50.0% | 167 | 0.0% | 0.00% | – |
| Q4 2022 | $2 | -99.8% | 167 | +81.5% | 0.00% | – |
| Q3 2022 | $1,000 | 0.0% | 92 | 0.0% | 0.00% | – |
| Q2 2022 | $1,000 | 0.0% | 92 | 0.0% | 0.00% | – |
| Q1 2022 | $1,000 | -50.0% | 92 | 0.0% | 0.00% | – |
| Q4 2021 | $2,000 | – | 92 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Medicxi Ventures Management (Jersey) Ltd | 7,464,572 | $76,885,092 | 22.93% |
| Propel Bio Management, LLC | 869,927 | $8,960,248 | 5.81% |
| Catalys Pacific, LLC | 721,962 | $7,436,208 | 5.61% |
| Checkpoint Capital L.P. | 875,000 | $9,012,500 | 5.43% |
| Frazier Life Sciences Management, L.P. | 10,109,279 | $104,125,574 | 4.87% |
| Carlyle Group Inc. | 3,496,808 | $35,842,282 | 3.40% |
| Decheng Capital LLC | 850,000 | $8,755,000 | 2.68% |
| Saturn V Capital Management LP | 593,306 | $6,111,052 | 2.31% |
| ORACLE INVESTMENT MANAGEMENT INC | 225,000 | $2,317,500 | 2.16% |
| Ghost Tree Capital, LLC | 600,000 | $6,180,000 | 1.94% |